Because type 2 diabetes increases fracture risk despite patients often having normal or high bone mineral density (BMD) theres growing concern about how these medications might influence bone health during GLP1 treatment
Since its approved for type 2 diabetes rather than weight loss, insurance coverage may vary depending on the prescription reason
Each increment in BMI of 5 kg/m 2 greater than 22,525,0 kg/m 2 corresponds to a rise in overall mortality of 30% ( Obesity pathophysiology is multifactorial and involves social, psychological and behavioral factors, genetic and metabolic predisposition (5)
Meaning, it stimulates your pituitary gland to produce more human growth hormone
Rothberg AE, McEwen LN, Kraftson AT, et al
Navigating the Transition Off GLP-1s Stopping a GLP-1 is rarely as simple as skipping a dose